Danaher (DHR) Tops Q3 EPS by 14c; offers outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Danaher (DHR) PT Lowered to $277 at Baird
October 23, 2024 6:25 AM EDTBaird analyst Catherine Schulte lowered the price target on Danaher (NYSE: DHR) to $277.00 (from $278.00) while maintaining a Outperform rating.
The analyst comments "Maintain Outperform rating, new $277 price target (-$1). DHR reported 3Q results ahead of expectations, driven by Biotechnology and Cepheid respiratory upside.... More
Danaher (DHR) PT Lowered to $275 at Leerink Partners
October 23, 2024 6:05 AM EDTLeerink Partners analyst Puneet Souda lowered the price target on Danaher (NYSE: DHR) to $275.00 (from $280.00) while maintaining a Outperform rating.
The analyst comments "Bottom Line: We see DHR as the leader in the highly attractive, spec'd-in and recurring rev market of bioprocess tools,... More
